Orphazyme investor following muscle wasting disappointment: "Now everything has to run smoothly in 2021"

The rest of 2021 has to run perfectly for Orphazyme, according to portfolio manager, following the pharmaceutical firm's recent and disappointing study with main candidate arimoclomol for the muscle wasting disease IBM.
Photo: Orphazyme/PR
Photo: Orphazyme/PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

Following disappointing results for Orphazyme's main candidate arimoclomol against muscle wasting disease inclusion body myositis (IBM), which decreased the share price over 30 percent within a single trading day, the firm has two chances left which must be successful in order to set the company right again.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading